Statin use in HCV patients may lower risk of death, decompensation
Use of direct-antiviral agents helps overcome hepatitis C recurrence in liver transplant patients
Hepatitis C screening essential to help catch patients with advanced liver fibrosis
Cancer rates among patients with hepatitis C are increased compared to those not infected
ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
Merck's Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
EASL Recommendations on Treatment of Hepatitis C 2015
Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease
Daclatasvir-sofosbuvir treatment highly effective in patients with HCV and HIV co-infection
Hepatitis C Infection Linked to Increased Risk of Heart Disease
Janssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
CNIO Researchers Link Telomeres to the Origins of Liver Diseases such as Chronic Hepatitis and Cirrhosis
HCV Advocate Mid-Month Newsletter
April 15, 2015
Overview of HCV Transmission & Prevention
Read about the ways that hepatitis C is transmitted and how to prevent transmission of hepatitis C:
Check it out!
Tips for Using This Site:
Here are a few tips to help you find what you're looking for on our site:
- Click on a category button on the top left for a content preview
of each section.
- Use the "Special Features" box on the left side of
the home page to quickly go to frequently visited links.
- Search this site from any page by using the Google Custom Search field in the top banner.
- Any time you want to return to the home page, click on the upper left hand corner"HCV Advocate."
Sign Up for Email Updates
Follow us on Twitter
Join us on Facebook